(A) $1,093,000,000 for fiscal year 2022.
(B) $1,296,000,000 for fiscal year 2023.
(C) $1,680,000,000 for fiscal year 2024.
(D) $1,974,000,000 for fiscal year 2025.
(E) $2,156,000,000 for fiscal year 2026.
(b) ALLOCATION AND LIMITATIONS.—
(1) SUPPLEMENT AND NOT SUPPLANT.—The amounts authorized to be appropriated by subsection (a) shall supplement, and not supplant, any other amounts previously authorized to be appropriated for the purposes described in such subsection.
(2) PROHIBITION ON USE OF FUNDS FOR CONSTRUCTION.—None of the amounts appropriated pursuant to the authorization in subsection (a) may be used for construction.

SA 1937. Mr. RUBIO submitted an amendment intended to be proposed to amendment SA 1502 proposed by Mr. SCHUMER to the bill S. 1260, to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes; which was ordered to lie on the table; as follows:

At the appropriate place in subtitle A of title I of division F, insert the following:

SEC. 61___. REQUIREMENT OF CERTIFICATION OF LABORATORIES.

Section 353 of the Public Health Service Act (42 U.S.C. 263a) is amended—
(1) by redesignating subsection (q) as subsection (r); and
(2) by inserting after subsection (p) the following:
''(q) TIES TO THE PEOPLE'S REPUBLIC OF CHINA.—
''(1) IN GENERAL.—Each certificate issued by the Secretary under this section shall state whether—
''(A) the laboratory;
''(B) the company that owns or manages the laboratory; or
''(C) any subcontractors or subsidiaries of such a laboratory or company,
is an entity described in paragraph (2).
''(2) ENTITY DESCRIBED.—An entity described in this paragraph is an entity—
''(A)(i) that is engaged in the biological, microbiological, serological, chemical, immuno-hematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, people of the United States; or
''(ii) that handles or has access to any data related to people of the United States that is derived from any activity described in clause (i); and
''(B)(i) over which control is exercised or exercisable by the Government of the People's Republic of China, a national of the People's Republic of China, or an entity organized under the laws of the People's Republic of China; or
''(ii) in which the Government of the People's Republic of China has a substantial interest.''.

SA 1938. Mr. RUBIO submitted an amendment intended to be proposed to amendment SA 1502 proposed by Mr. SCHUMER to the bill S. 1260, to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes; which was ordered to lie on the table; as follows:

At the appropriate place in subtitle A of title I of division F, insert the following:

SEC. 61___. ANNUAL REPORTING REGARDING GRANTEE TIES TO FOREIGN GOVERNMENTS.

Title IV of the Public Health Service Act is amended by inserting after section 403C (42 U.S.C. 283a–2) the following:

''SEC. 403C–1. ANNUAL REPORTING REGARDING GRANTEE TIES TO FOREIGN GOVERNMENTS.

''(a) IN GENERAL.—On an annual basis, the Director of NIH shall submit to the Committee on Health, Education, Labor, and Pensions, the Committee on Foreign Relations, and the Select Committee on Intelligence of the Senate, and to the Committee on Energy and Commerce, the Committee on Foreign Affairs, and the Permanent Select Committee on Intelligence of the House of Representatives, a report on any ties to foreign governments that researchers funded by grants from the National Institutes of Health have and that are not properly disclosed, vetted, and approved by the National Institutes of Health, including the status of any ongoing National Institutes of Health compliance reviews related to such ties and any administrative actions taken to address such concerns.
''(b) REQUIREMENT.—The Committees receiving the reports under subsection (a) shall keep confidential, and shall not release, any provision of such a report that is related to an ongoing National Institutes of Health compliance review.''.

SA 1939. Mr. RUBIO submitted an amendment intended to be proposed to amendment SA 1502 proposed by Mr. SCHUMER to the bill S. 1260, to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes; which was ordered to lie on the table; as follows:

At the appropriate place in subtitle A of title I of division F, insert the following:

SEC. 61___. NIH STRATEGIC PLAN.

Section 402(m)(2) of the Public Health Service Act (42 U.S.C. 282(m)(2)) is amended—
(1) in subparagraph (E), by striking ''; and'' and inserting a semicolon;
(2) by redesignating subparagraph (F) as subparagraph (G); and
(3) by inserting after subparagraph (E) the following:
''(F) address national security issues, including ways in which the National Institutes of Health can engage with other Federal agencies to modernize the national security strategy of the National Institutes of Health; and''.

SA 1940. Mr. RUBIO submitted an amendment intended to be proposed to amendment SA 1502 proposed by Mr. SCHUMER to the bill S. 1260, to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes; which was ordered to lie on the table; as follows:

At the end of subtitle B of title II of division E, add the following:

SEC. 5214. REVIEWS BY COMMITTEE ON FOREIGN INVESTMENT IN THE UNITED STATES OF COVERED TRANSACTIONS INVOLVING GENETIC INFORMATION.

(a) REQUIREMENTS FOR REVIEWS.—
(1) MANDATORY DECLARATIONS.—Section 721(b)(1)(C)(v)(IV) of the Defense Production Act of 1950 (50 U.S.C. 4565(b)(1)(C)(v)(IV)) is amended—
(A) by redesignating items (cc) through (gg) as items (dd) through (hh), respectively; and
(B) by inserting after item (bb) the following:
''(cc) COVERED TRANSACTIONS INVOLVING GENETIC INFORMATION.—The parties to a covered transaction shall submit a declaration described in subclause (I) with respect to the transaction if the transaction involves an investment described in subsection (a)(4)(B)(iii)(III) by a foreign person in a United States business that maintains or collects information about genetic tests of United States citizens, including any such information relating to genomic sequencing.''.
(2) CONSULTATION WITH SECRETARY OF HEALTH AND HUMAN SERVICES.—Section 721(k)(6) of the Defense Production Act of 1950 (50 U.S.C. 4565(k)(6)) is amended—
(A) by striking ''The chairperson'' and inserting the following:
''(A) IN GENERAL.—The chairperson''; and
(B) by adding at the end the following:
''(B) COVERED TRANSACTIONS INVOLVING GENETIC INFORMATION.—The chairperson shall consult with the Secretary of Health and Human Services in any review or investigation under subsection (a) of a covered transaction that involves an investment described in subsection (a)(4)(B)(iii)(III) by a foreign person in a United States business that maintains or collects information about genetic tests of United States citizens, including any such information relating to genomic sequencing.''.
(3) REGULATIONS.—Not later than 180 days after the date of the enactment of this Act, the Committee on Foreign Investment in the United States shall prescribe regulations to carry out the amendments made by this subsection.

(b) EXPANSION OF COMMITTEES RECEIVING ANNUAL TESTIMONY FROM COMMITTEE ON FOREIGN INVESTMENT IN THE UNITED STATES.—Section 721(o) of the Defense Production Act of 1950 (50 U.S.C. 4565(o)) is amended—
(1) in paragraph (1), in the matter preceding subparagraph (A), by striking ''the Committee on Financial Services of the House of Representatives and the Committee on Banking, Housing, and Urban Affairs of the Senate'' and inserting ''the committees specified in paragraph (2)'';
(2) by redesignating paragraph (2) as paragraph (3); and
(3) by inserting after paragraph (1) the following:
''(2) COMMITTEES SPECIFIED.—The committees specified in this paragraph are—